Tian-Xiang Shi

Title: Innovations in Immunology by Inventor Tian-Xiang Shi

Introduction

Tian-Xiang Shi is a notable inventor based in Pinole, California, who has made significant contributions to the field of immunology. With a total of three patents to his name, his work focuses on the development of bispecific antibodies that have the potential to revolutionize cancer treatment.

Latest Patents

One of his latest patents is titled "Monoclonal anti-multiple drug resistance antibody, methods of production." This invention pertains to the field of immunology, specifically addressing antibodies and their production. It details the creation of bispecific antibodies, hybrid hybridomas that produce them, and the purification processes involved. These bispecific monoclonal antibodies are designed to target both the human multi-drug resistance antigen, P-glycoprotein, and the human Fc.gamma. receptor III (hFc.gamma.RIII). Such innovations are crucial in the fight against cancer, as they enhance the ability to kill cancer cells effectively.

Another significant patent by Tian-Xiang Shi is "Bispecific antibodies, methods of production and use thereof." Similar to his previous work, this invention also focuses on bispecific antibodies and their production. It outlines the processes for creating hybrid hybridomas and the purification of these antibodies. The specific examples provided in this patent further emphasize the potential of bispecific monoclonal antibodies in targeting cancer cells, thereby improving therapeutic outcomes.

Career Highlights

Tian-Xiang Shi is associated with Chiron Corporation, where he continues to advance his research in immunology. His work has garnered attention for its innovative approach to addressing drug resistance in cancer treatment. The impact of his inventions is significant, as they contribute to the ongoing efforts to develop more effective cancer therapies.

Collaborations

Tian-Xiang Shi collaborates with David B Ring, a fellow researcher, to further enhance the scope and application of their work in immunology. Their partnership exemplifies the collaborative spirit that drives innovation in scientific research.

Conclusion

Tian-Xiang Shi's contributions to the field of immunology through his patents on bispecific antibodies represent a promising advancement in cancer treatment. His work at Chiron Corporation and collaborations with other researchers highlight the importance of innovation in addressing complex medical challenges.